One of the most studied probiotics in the world

BioGaia’s probiotic products with L. reuteri are among the most scientifically well-documented probiotics in the world with regard to both efficacy and safety.

BioGaia’s different strains of L. reuteri have been studied in more than 260 clinical trials involving over 22,000 people of all ages (Dec 2023).

Studies have been performed on the following:

  • Infantile colic and digestive health in children
  • Immune modulation and infection protection
  • Respiratory infections
  • Antibiotic-associated side effects, such as diarrhea
  • Treatment of Helicobacter pylori infection
  • Acute diarrhea
  • Oral health, such as gingivitis and periodontitis
  • Irritable bowel syndrome (IBS)
  • Osteopenia
  • Autism spectrum condition
  • Urinary tract infections

Clinical studies

Research on bacteria

In the past decade, research on bacteria and their significance to our health has increased. At BioGaia, we have been researching Limosilactobacillus reuteri (formerly Lactobacillus reuteri) for more than 30 years. During the years, we built a unique research network of specialists at research institutes worldwide. Together we have learned and gained knowledge about several L. reuteri bacteria strains for various conditions.

Our Research Network

Clinical trials supporting the use of BioGaia probiotics ​

L. reuteri Protectis, Prodentis, Pharax, Gastrus and Osfortis


studies in 7,517 subjects

Infants 0-12 months


studies in 3,414 subjects

Toddlers 13-36 months


studies in 4,585 subjects

Children 3-18 years


studies in 7,118 subjects

Adults >18 years